Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment
Sponsor: Supernus Pharmaceuticals, Inc.
Listed as NCT02618408, this PHASE3 trial focuses on Attention Deficit Hyperactivity Disorder (ADHD) and remains completed. Sponsored by Supernus Pharmaceuticals, Inc., it has been updated 13 times since 2016, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Nov 2023 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Dec 2022 — Jul 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
May 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Supernus Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .